Losses increase slightly at drug firm BioCryst
Durham, N.C. —
A year ago, BioCryst reported a loss of $10.6 million.
The company reported its financials before the markets opened Thursday.
BioCryst revenues increased to $12 million from $10.5 million a year ago, driven primarily by its contract with the U.S. Department of Health and Human Services to develop the flu treatment Peramivir.
Research and development costs climbed $1 million to $19.2 million and general expenses increased $700,000 to $3.8 million, the company said.
BioCryst employs some 50 people with 30 located at its Durham research and development operation.
For the financial report, read here.
Get the latest news alerts: Follow LTW at Twitter.
Log in or upgrade to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- NC Biotech Center braces for worst as Senate slashes budget, too
- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows